Your session is about to expire
← Back to Search
Immunomodulator
STAT-205 for COVID-19
Phase 1
Waitlist Available
Led By George Azar, MD
Research Sponsored by Cytocom, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Has a diagnosis of chronic heart disease
Has hypertension requiring at least one oral medication for treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 30
Awards & highlights
Study Summary
This trial is testing if an experimental drug can help people with mild COVID-19 who are at high risk for disease progression.
Eligible Conditions
- COVID-19
- Coronavirus
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1 to day 30
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 30
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proportion of patients who demonstrate progression of COVID-19 disease
Side effects data
From 2019 Phase 2 trial • 29 Patients • NCT030085907%
Dizziness
3%
Infections, minor viral or bacterial
3%
Ankle injury
3%
Fatigue
3%
Lip and tongue swelling
3%
Dermatitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
During Placebo Treatment
During Naltrexone Treatment
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: STAT-205Experimental Treatment1 Intervention
Dosing Period 1: 22.5 mg STAT-205 (five 4.5 mg capsules) Dosing Period 2: 4.5 mg STAT-205 (one capsule)
Group II: PlaceboPlacebo Group1 Intervention
Dosing Period 1: Placebo (five capsules) Dosing Period 2: Placebo (one capsule)
Find a Location
Who is running the clinical trial?
Cytocom, Inc.Lead Sponsor
George Azar, MDPrincipal InvestigatorClinical Research Center of Florida
Jennifer Veltman, MDPrincipal InvestigatorLoma Linda University
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger